Investor Presentaiton
Internal R&D strengths are amplified through extensive network of
external partnerships
SevenBridges
biobank TEMPUS
COTA
PicnicHealth
Memorial Sloan Kettering
Cancer Center
editas
Genes & Health
strandiji
TWIST
ENVISAGENICS
-ArsenalBio
Guardian
RESEARCH NETWORK
1-O
International
Immuno-Oncology
Network
indivumed Concert Al
GNS HEALTHCARE
CENTURY
THERAPEUTICS
Fred Hutch
Cancer Center
Peter Mac
Peter MacCallum Cancer Centre
Victoria Australia
Eisai
→volastra
----
MEDIC
Immatics
药明巨诺
B
A-ALPHA BIO
SGC
CHARM
THERAPEUTICS
flatiron
FINNGEN
CROHN'S
&COLITIS
FOUNDATION
NEW YORK
GENOME CENTER
HITGEN
Scripps Research
ADNI
A
AVIDITY
BIOSCIENCES
insitro
AMPHISTA
THERAPEUTICS
prothena
DARWIN
HEALTH
evotec
熊本大学
EMORY
PRECISION THERAPEUTICS for CANCER MEDICINE
Kumamoto University
UNIVERSITY
REPARE
THERAPEUTICS
SyntheX
PathAl
UNIVERSITY OF
OXFC
gentibio
NORDIC BIOSCIENCE
Roche
santaris
pharma a/s
Fulcrum
Therapeutics
Logon
OCTANT
IMIDomics
Agilent
BD
Adaptive
BIOCARTIS illumina
Thermo Fisher
SCIENTIFIC
HEMATOGENIX
UNIVERSITY
OF MIAMI
Queen Mary
University of London
somalogic
MAYO
CLINIC
МРААСТ
THE ROYAL MARSDEN
biopôle
Open Targets
Exscientia
KeyBioscience
SKYHAWK
evotec
THERAPEUTICE TUBULIS
SCHRÖDINGER.
Incentive Molecular
Halozyme
beLAB2122
LAB282
Templates
JW Therapeutics
Neuroscience Cardiovascular
Protein
Degradation
Immunology
Oncology &
Hematology
Computational
Biology
Small Molecule
Drug Discovery
Ill Bristol Myers Squibb™
Illi Bristol Myers Squibb™
> 100 active strategic collaborations
BMS also has an extensive network of over
150 academic research alliances
Translational
Medicine
DxTerity
beLAB1407
JOHNS HOPKINS
UNIVERSITY
Cross-
Therapeutic
Mount
Sinai Penn
COLUMBIA
UNIVERSITY
Discovery
Biotherapeutics
X
CYTOMX
THERAPEUTICS
zymeworks
RECOMBINANT ANTIBODY NETWORK
Adimab
Not for Product Promotional Use
49View entire presentation